Multifunctional Aryl Sulfonium Decavanadates: Tuning the Photochromic and Heterogeneous Oxidative Desulfurization Catalytic Properties Using Salicylaldehyde-type Functional Moieties on Counterions.

Multifunctional materials based on polyoxovanadates (POVs) have rarely been reported. Herein, we used aryl sulfonium counterions (ASCIs) bearing a salicylaldehyde-type functionality to tune the properties of decavanadate ([VO])-based hybrids for their application in photochromism and heterogeneous oxidative desulfurization (ODS) catalysis. The counterions FHPDS ((3-formyl-4-hydroxyphenyl)dimethylsulfonium), DFHPDS ((3,5-diformyl-4-hydroxyphenyl)dimethylsulfonium), and EFPDS ((4-ethoxy-3-formylphenyl)dimethylsulfonium) were clubbed with the decavanadate cluster to generate the hybrids (FHPDS)[HVO](HO) (), (DFHPDS)[HVO](HO) (), and (EFPDS)[HVO](HO) ().

Tests detecting biomarkers for screening of colorectal cancer: What is on the horizon?

Aim: To identify new and emerging screening tests for colorectal cancer (CRC) that involves detection of various biomarkers like blood, DNA and RNA in samples of faeces, tissue or blood. Current practice: Screening for CRC can be done by bowel visualisation techniques and tests that measure biomarkers. The Bowel Cancer Screening Programme (BCSP) in England uses a guaiac faecal occult blood test.

Prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief.

This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief. The ERG report is based on the manufacturer's submission (MS) to the National Institute for Health and Clinical Excellence as part of the single technology appraisal process. In the submission, quality-of-life data [Patient Assessment of Constipation Quality of Life (PAC-QOL) and Patient Assessment of Constipation Symptoms (PAC-SYM) questionnaires] from trials of prucalopride were extrapolated to EQ-5D (European Quality of Life-5 Dimensions) data and used to inform effectiveness in an economic model.

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

Background: Rheumatoid arthritis (RA) is an inflammatory condition that typically causes a symmetrical chronic arthritis. Timely use of disease-modifying antirheumatic drugs (DMARDs) is an essential aspect of disease management, but many patients may not respond even when conventional agents are used optimally.

Objective: To assess the clinical effectiveness and cost-effectiveness of adalimumab (ADA), etanercept (ETN), infliximab (IFX), rituximab (RTX) and abatacept (ABT) when used in patients with RA who have tried conventional agents and have failed to improve after trying a first tumour necrosis factor (TNF) inhibitor.